Vancouver, Canada, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the 'Company'), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a non-binding Letter of Intent (“LOI”) to acquire 51% stake in a leading intelligent EV (electric vehicles) wireless charging solutions for automated parking systems and autonomous mobile platforms company (the “Acquired Company”)..

加拿大温哥华，2026年8月3日（环球电讯社）——临床阶段生物科技公司Clearmind Medicine Inc.（纳斯达克股票代码：CMND）（以下简称“Clearmind”或“公司”）专注于发现和发展新型、非致幻的第二代迷幻神经可塑性衍生疗法，以解决主要未被充分治疗的健康问题。今日宣布，该公司已签署一份无约束力的意向书（“LOI”），拟收购一家领先的智能电动汽车（EV）无线充电解决方案公司的51%股权，该公司的解决方案适用于自动停车系统和自主移动平台（以下简称“被收购公司”）。

The Acquired Company develops intelligent wireless charging solutions for automated parking systems and autonomous mobile platforms. Based on proprietary technology featuring smart communication, dynamic energy management, and continuous charging up to 10 kW, the system requires no cables, no manual connections, or traditional charging infrastructure.

被收购公司专为自动泊车系统和自主移动平台开发智能无线充电解决方案。该系统基于专有技术，具备智能通信、动态能量管理以及高达10千瓦的持续充电能力，无需电缆、人工连接或传统充电基础设施。

It integrates seamlessly with robotic parking systems while enabling real-time energy management. As one of the few companies worldwide commercially deploying dedicated wireless charging for automated parking - and among the first of its kind - the technology is designed to advance smart parking infrastructure, autonomous vehicles, and future urban environments by significantly improving operational efficiency, safety, and user experience..

它与机器人停车系统无缝集成，同时实现实时能源管理。作为全球少数几家商业化部署自动泊车专用无线充电技术的公司之一，也是该领域的先驱者，这项技术旨在通过显著提升运营效率、安全性和用户体验，推动智能停车基础设施、自动驾驶汽车以及未来城市环境的发展。

Under the terms of the LOI, Clearmind will acquire the majority stake of the Acquired Company for an aggregate purchase price of $2.5 million (the “Acquisition”). In addition, in connection with and as a condition to the closing of the Acquisition (the “Closing”), the Company shall extend a loan to the Acquired Company in the principal amount of $1.5 million (the “Loan”).

根据意向书（LOI）的条款，Clearmind将以250万美元的总收购价收购目标公司的多数股权（以下简称“本次收购”）。此外，作为本次收购交割（以下简称“交割”）的相关事项及前提条件，公司应向目标公司提供一笔本金为150万美元的贷款（以下简称“该贷款”）。

The Loan shall bear interest at a rate of 4% per annum and shall be repaid on the two year anniversary of the Closing..

该贷款应按年利率4%计息，并应在交割日两周年之际偿还。

The Closing of the Acquisition is subject to the execution of definitive agreements, final due diligence and the satisfaction of certain closing conditions.

本次收购的交割须以签署最终协议、完成最终尽职调查以及满足若干交割条件为前提。

About Clearmind Medicine Inc.

关于Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements..

Clearmind 是一家处于临床阶段的神经可塑性药物生物技术公司，专注于发现和开发非致幻的第二代神经可塑性衍生疗法，以解决包括酒精使用障碍在内的广泛且未被充分满足的健康问题。其主要目标是研发基于致幻剂的化合物，并尝试将其作为受监管的药物、食品或补充剂进行商业化。

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio..

公司的知识产权组合目前由19个专利族组成，其中包括32项已授权专利。公司计划在适当时为其化合物申请更多专利，并将抓住机会获取更多知识产权，以扩充其知识产权组合。

Shares of Clearmind are listed for trading on Nasdaq under the symbol 'CMND.'

Clearmind 的股票在纳斯达克上市交易，股票代码为“CMND”。

For further information, visit:

欲了解更多信息，请访问：

https://www.clearmindmedicine.com

https://www.clearmindmedicine.com

or contact:

或联系：

Investor Relations

投资者关系

invest@clearmindmedicine.com

invest@clearmindmedicine.com

www.Clearmindmedicine.com

www.Clearmindmedicine.com

Forward-Looking Statements:

前瞻性声明：

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements.

本新闻稿包含《私人证券诉讼改革法案》及其他证券法律意义上的“前瞻性陈述”。诸如“预期”、“预计”、“打算”、“计划”、“相信”、“寻求”、“估计”等词语及类似表述或这些词语的变体，旨在识别前瞻性陈述。

For example, the Company is using forward-looking statements when it discusses the signing of definitive agreements for the acquisition of the Acquired Company, the timing and completion of the acquisition, and the satisfaction of closing conditions related to the acquisition. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain.

例如，当公司讨论签署关于收购目标公司的最终协议、收购的时间安排和完成情况，以及与收购相关的交割条件的满足时，所使用的是前瞻性陈述。前瞻性陈述并非历史事实，而是基于管理层当前的预期、信念和预测，其中许多就其性质而言具有固有的不确定性。

Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements.

上述预期、信念和预测均本着诚信原则作出。然而，无法保证管理层的预期、信念和预测能够实现，实际结果可能与前瞻性陈述中表达或暗示的内容存在重大差异。前瞻性陈述受各种风险和不确定性的影响，这些因素可能导致实际表现或结果与前瞻性陈述中表达的内容存在重大差异。

For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC.

有关影响本公司的风险和不确定性的更详细描述，请参阅本公司不时向美国证券交易委员会（“SEC”）提交的报告，包括但不限于本公司截至2025年10月31日财政年度的20-F表年报中详述的风险以及随后向SEC提交的文件。

Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to up.

前瞻性陈述仅反映作出该等陈述之日的情况。本公司不承担更新义务。